AWS launched Amazon Bio Discovery, an AI platform that provides direct access to foundation models for antibody drug discovery and routes results into an in-the-loop wet-lab workflow. The service is paired with an AI agent designed to select models for specific goals and evaluate which antibody candidates to synthesize and test. AWS said the workflow connects computational design to lab partners including Twist and Ginkgo, leveraging wet-lab capacity for rapid synthesis cycles. Early workflow examples cited by AWS include designing nearly 300,000 antibodies and moving the most promising candidates into testing. For the biotech sector, the launch highlights a shift toward enterprise-grade AI-enabled discovery infrastructure—potentially compressing the experiment iteration loop for early-stage antibody work.